Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
July 25 completes the deal, but don’t know if shares will be converted that day.
When does this stop trading and become part of Aurora is it this week
IHUB “Cannabis” discussion boards
Cannabis Australian
Canadian Weed!
California Gold Rush Hot Marijuana Stocks
Cannabis Canadian and U. S. Priced At $0.75 to $10.00
Cannabis Best Opportunity Stocks $0.10 to $0.75
Cannabis Investment Club (Cannabis stock picker contest)
Cannabis IPO Watch CA and US
Cannabis - smoke, vape, ingest, oil, etc.
MedReleaf to Sponsor Cancer Trial with Ontario Clinical Oncology
Group
MARKHAM, ON, July 12, 2018 -- /D.M.O. Newswire/ -- MedReleaf Corp. (TSX:LEAF) ("MedReleaf" or the "Company"), in collaboration with the Ontario Clinical Oncology Group ("OCOG") today announced it will sponsor a cancer trial to improve the management of cancer pain using medical grade cannabis oil.
The OCOG directed by Dr. Mark Levine will coordinate the trial. Dr. Marissa Slaven, a specialist in pain management and palliative care is the Principal Investigator. The study will be conducted at the HHS Juravinski Cancer Centre in Hamilton over a one-two year period. Patients with cancer related pain will be administered MedReleaf's uniquely formatted cannabis oil capsules with the objective of improving pain management.
Cancer patients experiencing pain despite other pain medications may be eligible to participate. The aim of the trial is to assess the effect of cannabis oil in relieving their symptoms and to gain information on the best oral dosing regimen. Patients will receive an oil combining THC and CBD.
FULL RELEASE: https://www.dailymarijuanaobserver.com/single-post/2018/07/12/LEAF-MEDFF-MedReleaf-to-Sponsor-Cancer-Trial-with-Ontario-Clinical-Oncology-Group
Don't know why we would be want to be part of Aurora. This stock seems to be doing pretty well on it's own.
MedReleaf and BioPharma Services Inc. announce Strategic Alliance
SOURCE: https://www.dailymarijuanaobserver.com/single-post/2018/05/29/LEAF-MEDFF-MedReleaf-and-BioPharma-Services-Inc-announce-Strategic-Alliance
TORONTO, May 29, 2018 /CNW/ - MedReleaf Corp. (TSX:LEAF) ("MedReleaf" or the "Company") and BioPharma Services Inc. (BioPharma) today announced they have entered into an exclusive agreement to conduct clinical research for cannabis and cannabis derived products. Under the agreement BioPharma will become an extension of MedReleaf's clinic development team.
BioPharma will provide medical, clinical, pharmacological and lab expertise to expedite MedReleaf's product strategy to support in-market products as well as products under development for registration in Canadian and international markets.
BioPharma is well positioned to accelerate MedReleaf's product development and clinical research programs through their international experience in running early phase clinical trials. MedReleaf and BioPharma will jointly provide scientific and regulatory guidance to clinical research studies supporting MedReleaf's product launches in the months to come.
"This strategic alliance sets us apart in the clinical research and development space for cannabis and cannabis derived products and will facilitate much needed cannabinoid therapies to assist in the treatment of pain, inflammatory conditions, mental health, palliative care and underserved therapeutic areas," said Angelo Fefekos, Senior Vice President Clinical Affairs and Quality Assurance at MedReleaf.
"We are very proud to work with MedReleaf in support of their cannabinoid natural health and drug strategy. This alliance is a great example of BioPharma's capabilities as a Phase I industry leader with expertise in CNS, pain and abuse liability," said Renzo DiCarlo, CEO at BioPharma Services, Inc.
About MedReleaf (TSX.LEAF)
Canada's most awarded licensed producer, MedReleaf is an R&D-driven company dedicated to innovation, operational excellence and the production of industry leading, top-quality cannabis. Sourced from around the world and carefully cultivated in one of two state-of-the-art ICH-GMP and ISO 9001 certified facilities in Ontario, with a third facility currently in development, a full range of premium MedReleaf products are delivered to the global medical market. We serve the therapeutic needs of patients seeking safe, consistent and effective medical cannabis and provide a compelling product offering for the adult-use recreational market.
For more information on MedReleaf, its products, research and how the company is helping patients #livefree, please visit MedReleaf.com or follow @medreleaf
About BioPharma Services Inc.
BioPharma Services Inc. is a full-service Contract Research Organization (CRO) specializing in the conduct of Phase I/IIa and Bioequivalence clinical trials for international pharmaceutical companies worldwide. BioPharma has clinical facilities both in the USA and Canada with a total capacity of 300 beds with access to healthy volunteers and special populations. Headquartered in Toronto, Canada, BioPharma's comprehensive services also include Bioanalysis at our GLP Certified Laboratory, Scientific and Regulatory Affairs, Biostatistics and Safety Data Analysis (CDISC), Medical Writing and Data Management.
When do our shares convert to ACB ?
Aurora and MedReleaf File Arrangement Agreement and More
SOURCE: https://www.dailymarijuanaobserver.com/single-post/2018/05/25/ACB-ACBFF-Aurora-and-MedReleaf-File-Arrangement-Agreement-and-More
EDMONTON and MARKHAM, ON, May 25, 2018 /CNW/ - Aurora Cannabis Inc. ("Aurora") (TSX:ACB) and MedReleaf Corp. ("MedReleaf") (TSX:LEAF) today announced the filing on SEDAR of the arrangement agreement dated May 14, 2018 between Aurora and MedReleaf (the "Original Agreement"), as amended by an amending agreement (the "Amending Agreement"), and the material change reports in respect of the previously announced transaction whereby Aurora intends to acquire all of the issued and outstanding common shares of MedReleaf (the "Material Change Reports").
Aurora and MedReleaf have agreed to amend the Original Agreement to include, in the consideration payable to holders of MedReleaf's common shares, (each a "MedReleaf Share"), $0.000001 in cash for each MedReleaf Share. As a result, the consideration under the arrangement has been increased from 3.575 Aurora common shares for each MedReleaf Share to 3.575 Aurora common shares and $0.000001 in cash for each MedReleaf Share. Taxable Canadian resident MedReleaf shareholders will be entitled to elect to receive tax-deferred roll-over treatment in connection with the acquisition by Aurora of their MedReleaf Shares. If a MedReleaf shareholder does not, or is unable to, make an election, then Aurora's acquisition cost for such shareholder's MedReleaf Shares will generally be equal to the fair market value of such shares.
For further information, please visit www.sedar.com to view the Original Agreement, the Amending Agreement and the Material Change Reports.
About Aurora
Aurora's wholly-owned subsidiary, Aurora Enterprises Inc., is a licensed producer of medical cannabis pursuant to Health Canada's Access to Cannabis for Medical Purposes Regulations ("ACMPR"). The Company operates a 55,200 square foot, state-of-the-art production facility in Mountain View County, Alberta, known as "Aurora Mountain", and a second 40,000 square foot high-technology production facility known as "Aurora Vie" in Pointe-Claire, Quebec on Montreal's West Island. In January 2018, Aurora's 800,000 square foot flagship cultivation facility, Aurora Sky, located at the Edmonton International Airport, was licensed. Once at full capacity, Aurora Sky is expected to produce over 100,000 kg per annum of cannabis. Aurora is completing a facility in Lachute, Quebec utilizing its wholly owned subsidiary Aurora Larssen Projects Inc.
The Company's wholly-owned subsidiary CanniMed Therapeutics Inc. ("CanniMed") is Canada's most experienced licensed producer of medical cannabis, with over 20,000 kg per annum in funded capacity. CanniMed forms the heart of Aurora's Medical Cannabis Centre of Excellence, aimed at product and market development.
Aurora also owns Berlin-based Pedanios GmbH, the leading wholesale importer, exporter, and distributor of medical cannabis in the European Union. The Company owns 51% of Aurora Nordic, which will be constructing a 1,000,000 square foot hybrid greenhouse in Odense, Denmark. The Company offers further differentiation through its acquisition of BC Northern Lights Ltd. and Urban Cultivator Inc., industry leaders, respectively, in the production and sale of proprietary systems for the safe, efficient and high-yield indoor cultivation of cannabis, and in state-of-the-art indoor gardening appliances for the cultivation of organic microgreens, vegetables and herbs in home and professional kitchens.
Aurora holds a 25% ownership interest in Alcanna Inc. ("CLIQ"), one of Western Canada's largest retail chains of liquor stores, who are developing a cannabis retail network in Western Canada. In addition, the Company holds approximately 17.23% of the issued shares in leading extraction technology company Radient Technologies Inc, and holds 52.7% of Hempco Food and Fiber Inc. Aurora is also the cornerstone investor in two other licensed producers, with a 22.9% stake in Cann Group Limited, the first Australian company licensed to conduct research on and cultivate medical cannabis, and a 17.62% stake in Canadian producer The Green Organic Dutchman Ltd., with options to increase to majority ownership. Finally, the Company owns a 9.14% stake in CTT Pharmaceutical, an innovative product development company within the cannabis space.
Aurora's Common Shares trade on the TSX under the symbol "ACB", and are a constituent of the S&P/TSX Composite Index
About MedReleaf
Canada's most awarded licensed producer, MedReleaf is an R&D-driven company dedicated to innovation, operational excellence and the production of top-quality cannabis. Sourced from around the world and carefully cultivated in one of two state-of-the-art ICH-GMP and ISO 9001 certified facilities in Ontario Canada, with a third facility currently in development, premium MedReleaf products are delivered to the global medical market. MedReleaf serves the therapeutic needs of patients seeking safe, consistent and effective medical cannabis and provides a compelling product offering for the adult-use recreational consumer.
For more information on MedReleaf, its products, research and how the company is helping patients #livefree, please visit MedReleaf.com or follow @medreleaf.
Forward looking statements
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "potential", "believe", "intend" or the negative of these terms and similar expressions. Forward-looking statements in this news release includes, but is not limited to, the consideration to be received by shareholders of MedReleaf, which may fluctuate in value due to Aurora common shares forming the consideration. In particular, there can be no assurance that the transaction will be completed. Forward looking statements are based on certain assumptions regarding Aurora and MedReleaf, including expected growth, results of operations, performance, industry trends and growth opportunities. While Aurora and MedReleaf consider these assumptions to be reasonable, based on information currently available, they may prove to be incorrect. Readers are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements also necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; future legislative and regulatory developments; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the cannabis industry in Canada generally, income tax and regulatory matters; the ability of Aurora to implement its business strategies; competition; currency and interest rate fluctuations and other risks.
Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof, and thus are subject to change thereafter. Aurora and MedReleaf disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Factors that could cause anticipated opportunities and actual results to differ materially include, but are not limited to, matters referred to above and elsewhere in Aurora's and MedReleaf's public filings and the material change reports that will be filed in respect of this transaction, which are, or will be, available on SEDAR.
MedReleaf to Collaborate With CFL Alumni Association
SOURCE: https://www.dailymarijuanaobserver.com/single-post/2018/05/24/LEAF-MEDFF-MedReleaf-to-Collaborate-With-CFL-Alumni-Association
MARKHAM, ON, May 24, 2018 /CNW/ - MedReleaf Corp. (TSX:LEAF) ("MedReleaf" or the "Company"), today announced it will collaborate with the Canadian Football League Alumni Association ("CFLAA") in conducting an observational study on the benefits of medical cannabis in treating chronic pain and related ailments in retired professional athletes.
MedReleaf and the CFLAA recognize the opportunity to collaborate on this important study which will bring greater awareness to the potential health benefits of using medical cannabis in the treatment of ailments that include chronic pain. The joint observational study is scheduled to begin in the summer of 2018 with volunteer CFLAA member participants.
"We are excited to collaborate with the CFL Alumni Association on this significant observational study with legends in the Canadian athletic arena," said Neil Closner, MedReleaf CEO. "Through ongoing research, our understanding of the benefits of medical cannabis has grown significantly and we welcome the opportunity to apply our expertise in validating new patient therapies and contributing to positive patient outcomes for this exceptional group of former athletes."
"The CFLAA has always sought to make a difference by providing support to our alumni, many of whom experienced medical challenges following their athletic careers," said Leo Ezerins, CFLAA Executive Director. "In collaborating with MedReleaf we hope to gain further insight into the benefits of medical cannabis in managing chronic pain - insight that could be invaluable to our almost 2,000 alumni members."
About MedReleaf Corp.
Canada's most awarded licensed producer, MedReleaf is an R&D-driven company dedicated to innovation, operational excellence and the production of top-quality cannabis. Sourced from around the world and carefully cultivated in one of two state-of-the-art ICH-GMP and ISO 9001 certified facilities in Ontario Canada, with a third facility currently in development, premium MedReleaf products are delivered to the global medical market. MedReleaf serves the therapeutic needs of patients seeking safe, consistent and effective medical cannabis and provides a compelling product offering for the adult-use recreational consumer.
For more information on MedReleaf, its products, research and how the company is helping patients #livefree, please visit MedReleaf.com or follow @medreleaf
About the CFLAA
The Canadian Football League Alumni Association is 2,000 members strong and unites former CFL players, from across Canada, in support of sport, youth, and health related charitable causes. The CFLAA fosters a lifelong relationship between the Canadian Football League and its former players with a special focus on providing support to those alumni experiencing medical challenges resulting from their former athletic careers.
Have you seen the Aurora's presentation on how the proposed transaction buyout of Medreleaf, the offer and timelines, see page 6 and 7. You can search this presentation in Seekingalpha.com
Aurora Cannabis (ACBFF) To Acquire MedReleaf (MEDFF) - Slideshow
2:28 pm, Tue, May 15, 2018, by SA Transcripts
Read now »
dont get the logic? isnt this 23.04 US with the deal? c29.44-$23.04
I got a bad feeling about this, so I sold %70 and kept some free riding shares. I went to Canopy - seems like the better opportunity with them going over to the NYSE. I'd rather make mistakes on the side of caution than be left holding the bag.
If it's based on the same math as on the TSX, it's a ~16% boost in value.
So does it work? We get 3.576 shares of aurora if we hold one share of medreleaf? Seems to me excessive and how does it work in practice? Thanks novice here
Bazinga time kudos UnderOath!
I'm only holding on Canadian side so no clue how it's gonna work for the dual listed shareholders.
+2.45% on Canadian exchange now:)
YES -it's been known for awhile that this is for sale, but the best price wins so no telling who will own it. Money talks.
Think this is still considered being bought out. May account for the rise in share price. Bought at 6 bucks a share. Regret not buying more at that price.
Nice week here and not a squeak from anyone. LOL !
Been outperforming most others it the sector (% Gain) for the last month or so.
competitive - not aggressive. Expanding too quickly has ruined a lot of good companies. Baby steps is what I like.
Maybe, just want to see them keep up.
Aggressiveness is keeping the leaders in place.
They need to be seen as equally aggressive to attract market share. JMO
That's not the way I look at it. We have months of opportunities because laws aren't even in place yet. Being a buyout candidate is a good place to be. Give it 4-6 months.
Every day that goes by with no news hurts. IMO
No news, other than this is for sale.
Any news on M and A activity?
Given the increase in the stock price maybe they should be shopping for companies to fill any deficiencies they were hoping to resolve by being bought. JMO
Looks like the shorts here could be in trouble.
Check out the "Equity Short Interest" tab.
NO DEAL YET. Carry on.
Will resume at 1:45
If it's GWPH, we are golden !
MedReleaf responds to market rumors
1:02 PM ET 5/3/18 | Dow Jones
MARKHAM, ON, May 3, 2018 /CNW/ - MedReleaf Corp. ("MedReleaf" or the "Company") (TSX: LEAF) is aware of a recent news article speculating as to a potential transaction involving Aurora Cannabis. As a general policy, MedReleaf does not publicly comment on unusual market activity, rumors or speculation in the marketplace or any potential transaction unless, and until, a binding legal agreement to effect that transaction has been signed.
I;m with u there. Could be serious deals going down soon. Would be very easy for a monster US company to buy some of these established licensed producers.
Agree Jackie! Many think that big pharma or some of the big US beverage companies might swallow up the biggest of these companies in the future as well. IMO GLTA
Sounds good, this is not a pump. It shouldn't affect either company negatively. These potential acquisitions will happen more often as the bigger companies continue to snatch up smaller ones. Good strategy especially before legalization. These companies know that snagging these other smaller companies before legal day will be a huge move.
Lets hope it continues up. Been a long downwards run, almost time for a change north. Mother of berries! Great strain. Lets go :)
Good suggestion.
Hope it's great news and then fly time.
It looks like it is halted pending news, like ACBFF is also....more to come. IMO GLTA
This is a daily anomaly. GWPH is even worse. Never buy or sell at market for these weed stocks. NAME YOUR PRICE !
Followers
|
20
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
161
|
Created
|
06/26/17
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |